Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
172 hedge funds and large institutions have $542M invested in Meridian Bioscience Inc in 2017 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 51 reducing their positions, and 18 closing their positions.
71% more call options, than puts
Call options by funds: $262K | Put options by funds: $153K
16% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 51
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
1% more funds holding
Funds holding: 170 → 172 (+2)
8% less capital invested
Capital invested by funds: $592M → $542M (-$50M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.65M |
| 2 |
SCM
SG Capital Management
Chicago,
Illinois
|
+$5.23M |
| 3 |
Morgan Stanley
New York
|
+$4.12M |
| 4 |
Renaissance Technologies
New York
|
+$1.21M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$6.82M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.79M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$3.9M |
| 4 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$2.24M |
| 5 |
HEC
Hudson Executive Capital
New York
|
-$1.94M |
VIVO Hedge Fund Activity: Q3 2017 in Review
172 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q3 2017, worth a combined $542M — down 8.5% from $592M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VIVO positions and 18 closed out — a net gain of 2 holders — while 59 added to existing stakes and 51 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.65M. The largest seller was UBS Group, cutting an estimated $6.82M.
- 172 institutional investors held Meridian Bioscience Inc (VIVO) as of Q3 2017, up from 170 in Q2 2017.
- Funds reported $542M of Meridian Bioscience Inc stock for Q3 2017, down 8.5% quarter-over-quarter.
- 20 funds opened new Meridian Bioscience Inc positions in Q3 2017 and 18 closed out, a net change of +2 holders.
- The largest Meridian Bioscience Inc buyer in Q3 2017 was Millennium Management, an estimated $5.65M added.
- The largest Meridian Bioscience Inc seller in Q3 2017 was UBS Group, an estimated $6.82M sold.
Based on aggregated 13F filings for Q3 2017.